Drugs / calcium gluconate
calcium gluconate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CALCIUM GLUCONATE | — | 2017-06-15 | fda.gov ↗ |
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05973747 | Aug → Dec 2023 | pregnancy disorder | Stanford University | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT07555769 | Jun 2026 → Apr 2030 expected | urinary bladder neoplasm, urothelial carcinoma | Juan Luis Vásquez | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04958044 | May 2021 → Jun 2022 | esophageal cancer | Michael Patrick Achiam | Completed | No outcome recorded |
| Phase 1 | NCT01682499 | Aug 2012 → Aug 2014 | chemotherapy-induced neuropathy | Beth Israel Medical Center | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07217899 | Oct 2025 → Jul 2026 overdue | uterine disorder | University of Michigan | Recruiting | No outcome recorded |
| Phase 2 | NCT05958342 | Jun 2024 → Mar 2027 expected | hemorrhagic disease | Jason Sperry | Recruiting | No outcome recorded |
| Phase 2 | NCT02875587 | Oct 2016 → Aug 2018 | ovarian hyperstimulation syndrome | Aljazeera Hospital | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06820645 | May 2025 → Apr 2026 overdue | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT00977444 | Nov 2007 → Feb 2009 | osteoarthritis | Nucitec | Unknown | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05953376 | Jan → Dec 2025 | hemorrhagic disease | University of California, Irvine | Withdrawn | No outcome recorded |
| Phase 3 | NCT01099449 | Jun 2010 → Dec 2012 | chemotherapy-induced toxicity, colorectal cancer, peripheral neuropathy | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00998738 | Nov 2009 → Jul 2010 | breast carcinoma, peripheral neuropathy | Mayo Clinic | Terminated | No outcome recorded |
| Phase 3 | NCT00316914 | Jan 2006 → Jan 2008 | colorectal cancer, poisoning | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04491357 | Jun 2020 → Jun 2022 | — | University of Malaya | Unknown | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07714902 | Jun 2026 → Oct 2027 expected | — | Rambam Health Care Campus | Recruiting | No outcome recorded |
| — | NCT06235749 | Nov 2023 → May 2028 expected | — | Rambam Health Care Campus | Recruiting | No outcome recorded |
| — | NCT05198128 | Mar 2022 → Apr 2023 | ovarian hyperstimulation syndrome | Al-Azhar University | Unknown | No outcome recorded |
| — | NCT02580604 | Nov 2015 → Jul 2024 | osteoporosis | University of Colorado, Denver | Completed | No outcome recorded |
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03543917 Background | Aug 2017 → Aug 2018 | stroke disorder | Fundatia Bio-Forum | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00416715 Background | Oct 2006 → May 2010 | arthropathy, female breast carcinoma | University of Washington | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03473613 Comparator | Oct 2014 → Apr 2017 | ovarian hyperstimulation syndrome | Benha University | Completed | No outcome recorded |
| Phase 3 | NCT00354302 Background | Apr 2006 → Mar 2011 | female breast carcinoma, osteoporosis | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 3 | NCT00058188 Background | Mar 2003 → Nov 2008 | osteoporosis, prostate cancer | Northwestern University | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05661942 Comparator | Nov 2022 → Nov 2024 | atrial fibrillation, hypotensive disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06333691 Comparator | Oct 2022 → Feb 2024 | ovarian hyperstimulation syndrome | Minia University | Completed | No outcome recorded |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Calcium Gluconate | “intra-articular injections of sodium bicarbonate with a single (SBCG1) or double dose (SBCG2) of calcium gluconate administered monthly compared with methylprednisolone (MP)...” PMID 28469486 ↗ Feb 201724“intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in...” NCT05198128 ↗ “Calcium electroporation involves injection of calcium gluconate into the urinary bladder tumor followed by short, electric pulses (electroporation) with the transurethral electrode” NCT07555769 ↗ “Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours” NCT03543917 ↗ “The intervention is Calcium gluconate 1 gram/100ml 0.9% NaCl or 100ml 0.9% NaCl) over 5 minutes.” NCT05661942 ↗ |
| Known as | Calcarea gluconica | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Known as | Calcii gluconas | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Known as | Calcionate | “took IV infusion of calcium gluconate (Calcionate 10ml of 10% calcium gluconate, Memphis)” NCT06333691 ↗ |
| Known as | Calcium d-gluconate monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Known as | Calcium di-gluconate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Known as | Calcium gluconate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Known as | Calcium gluconate hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Known as | Calcium gluconate in sodium chloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Known as | Calcium gluconate monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Known as | Calglucon | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Known as | E-578 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Known as | H-f antidote | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Known as | INS NO.578 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Known as | INS-578 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Known as | NSC-744619 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2106119 ↗ |
| Modality | Small molecule | — CHEMBL2106119 ↗ |
| Route | Oral | “Given orally” NCT00058188 ↗ |